Hepatitis B in Pregnancy: Challenges and Treatment

Gastroenterology Clinics of North America

Volumn 40, Issue 2, 2011, Pages 355-372

  Degli Esposti, Silvia ^a,b   Shah, Dhvani ^a  

^a BROWN UNIVERSITY   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; Hepatitis B; Pregnancy; Vertical transmission

Indexed keywords

ADEFOVIR; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 10; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR; VIRUS DNA;

ANTIBODY DETECTION; ANTIGEN DETECTION; BLOOD ANALYSIS; BONE REMODELING; BREAST FEEDING; CLINICAL FEATURE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DETERMINATION; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATTY LIVER; FETAL WELL BEING; FETUS DEATH; FETUS DEVELOPMENT; GENETIC POLYMORPHISM; HEMATOCRIT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INDIVIDUALIZATION; INTRAUTERINE INFECTION; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER FAILURE; MATERNAL CARE; MATERNAL WELFARE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); NEUROLOGIC DISEASE; NON INVASIVE MEASUREMENT; NONHUMAN; OSTEOPOROSIS; PATIENT COUNSELING; PATIENT MONITORING; PATIENT REFERRAL; PERINATAL INFECTION; PERINATAL PERIOD; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL SCREENING; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TERATOGENICITY; THROMBOCYTE COUNT; VERTICAL TRANSMISSION; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 79956115380     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2011.03.005     Document Type: Review

References (55)

1. Institute of Medicine (IOM) Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C 2010, The National Academies Press, Washington, DC.
2. Goldstein S.T., Zhou F., Hadler S.C., et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34:1329-1339.
3. McMahon B.J., Alvard W.L., Hall D.B., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985, 151:599-603.
4. Centers for Disease Control and Prevention (CDC) Summary of notifiable diseases, United States, 2008. MMWR Morb Mortal Wkly Rep 2008, 57:1-94.
5. Alter M.J. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003, 39(Suppl 1):S64-S69.
6. Euler G.L., Wooten K.G., Baughman A.L., et al. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting and preventing perinatal transmission. Pediatrics 2003, 111:1192-1197.
7. Schrag S.J., Arnold K.E., Mohle-Boetani J.C., et al. Prenatal screening for infectious diseases and opportunities for prevention. Obstet Gynecol 2003, 102:753-760.
8. American College of Obstetricians and Gynecologists American Congress of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 86. Viral hepatitis in pregnancy. Obstet Gynecol 2007, 110:941-956.
9. Kim S.M., Lee K.S., Park C.J., et al. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 2007, 54:185-191.
10. Willis B.T., Wortley P., Wang S.A., et al. Gaps in hospital policies and practices to prevent perinatal transmission of HBV. Pediatrics 2010, 125:704-711.
11. Anderson T.A., Wexler D.L. States report hundreds of medical errors in perinatal hepatitis B prevention 2005, Immunization Action Coalition, St Paul (MN).
12. Burk R.D., Hwang L.Y., Ho G.Y., et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994, 170:1418-1423.
13. Beasley R.P., Hwang L.Y., Lin C.C., et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomized double-blind placebo-controlled trial. Lancet 1981, 2(8243):388-393.
14. Lee C., Gong Y., Brok J., et al. Effect of hepatitis B immunization in newborn infants of mothers positive for hepatitis surface antigen: systematic review and meta-analysis. BMJ 2006, 332:328-336.
15. Xu D.Z., Yan Y.P., Choi B.C., et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002, 67(1):20-26.
16. Zhang S.L., Yue Y.F., Bai G.Q., et al. Mechanism of intrauterine infection of hepatitis B virus. World J Gastroenterol 2004, 10(3):437-438.
17. Bai H., Zhang L., Ma L., et al. Relationship of hepatitis B infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism. World J Gastroenterol 2007, 13(26):3625-3630.
18. Hill J.B., Sheffield J.S., Kim M.J., et al. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002, 99:1049-1052.
19. Alexander J.M., Ramus R., Jackson G., et al. Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. Infect Dis Obstet Gynecol 1999, 7:283-286.
20. Englert Y., Lesage B., Van Vooren J.P., et al. Medically assisted reproduction in the presence of chronic viral diseases. Hum Reprod Update 2004, 10(20):149-162.
21. CDC Implementation of newborn hepatitis B vaccination-worldwide. MMWR Morb Mortal Wkly Rep 2008, 57(46):1249-1252.
22. Wang J.S., Chen H., Zhu Q.R. Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers. World J Gastroenterol 2005, 11(23):3582-3585.
23. Han G., Zhao W., Cao M., et al. A prospective and open-label study for the efficacy and safety of telbivudine (ldt) in pregnancy for the prevention of perinatal transmission of hepatitis B virus (HBV) to the infants. Hepatology 2010, 52(4):427A.
24. Plitt S.S., Somily A.M., Singh A.E. Outcomes from a Canadian public health prenatal screening program for hepatitis B: 1997-2004. Can J Public Health 2007, 98(3):194-197.
25. Wiseman E., Fraser M.A., Holden S., et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009, 190:489-492.
26. Andre F.E., Zuckerman A.J. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994, 44:144-151.
27. Tharmaphornpilas P., Rasdjarmrearnsook A.O., Plianpanich S., et al. Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination. Vaccine 2009, 27(44):6110-6115.
28. Zhu Q.R., Ge Y.L., Gu S.Q., et al. Relationship between cytokines gene polymorphism and susceptibility to hepatitis B virus intrauterine infection. Chin Med J 2005, 118(19):1604-1609.
29. Li X.M., Shi M.F., Yang Y.B., et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004, 10:3215-3217.
30. Xu Q., Xiao L., Lu X.B., et al. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol 2006, 12:3434-3437.
31. Xiao X.M., Li A.Z., Zhu Y.K., et al. Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet 2007, 96:167-170.
32. Connor E.M., Sperling R.S., Geiber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331(18):1173-1180.
33. Xu W.M., Cui Y.T., Wang L., et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009, 16(2):94-103.
34. Van Zonneveld M., van Nunen A.B., Niesters H.G., et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003, 10:294-297.
35. Nguyen G., Garcia R.T., Nguyen N., et al. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther 2009, 29:755-764.
36. Potthoff A., Rifai K., Wedemeyer H., et al. Successful treatment of fulminant hepatitis B during pregnancy. Gastroenterol 2009, 47(7):667-670.
37. Shaheen A.A., Myers R.P. The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver Int 2010, 30(2):275-283.
38. Sandhu B.S., Sanyal A.J. Pregnancy and liver disease. Gastroenterol Clin North Am 2003, 32:407-436.
39. Iwase H., Morise K., Kawase T., et al. Endoscopic injection sclerotherapy for esophageal varices during pregnancy. J Clin Gastroenterol 1994, 18:80-83.
40. Wong S., Chan L.Y., Yu V., et al. Hepatitis B carrier and perinatal outcome in singleton pregnancy. Am J Perinatol 1999, 16(9):485-488.
41. Safir A., Levy A., Sikuler E., et al. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int 2010, 30(5):765-770.
42. Lao T.T., Tse K.Y., Chan L.Y., et al. HBsAg carrier status and the association between gestational diabetes with increased serum ferritin concentration in Chinese women. Diabetes Care 2003, 26(11):3011-3016.
43. Hung J.H., Chu C.J., Sung P.L., et al. Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy. J Chin Med Assoc 2008, 71(3):155-158.
44. Tan H.H., Lui H.F., Chow W.C. Chronic hepatitis B virus (HBV) infection in pregnancy. Hepatol Int 2008, 2:370-375.
45. Ter Borg M.J., Leemans W.F., de Man R.A., et al. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008, 15:37-41.
46. Lin H.H., Wu W.Y., Kao J.H., et al. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics. J Gastroenterol Hepatol 2006, 21(3):605-609.
47. Powrie R.O. Principles for drug prescribing in pregnancy. Medical care of the pregnant patient 2008, 18-25. American College of Physicians Press, Philadelphia. 2nd ed. K. Rosene-Montella, E. Keely, L.A. Barbour, R. Lee (Eds.).
48. Bennetto-Hood C., Bryson Y.J., Stek A., et al. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. HIV Clin Trials 2009, 10(1):41-47.
49. Van Rompay K.K., Hamilton M., Kearney B., et al. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother 2005, 49(5):2093-2094.
50. Sakata H., Karamitsos J., Kundaria B., et al. Case report of interferon alfa therapy for multiple myeloma during pregnancy. Am J Obstet Gynecol 1995, 172(1):217-219.
51. Cohen S.M., Levy R.M., Jovanovich J.F., et al. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol 2009, 43(10):1008-1010.
52. Shah I. Lactic acidosis in HIV-exposed infants with perinatal exposure to antiretroviral therapy. Ann Trop Paediatr 2009, 29(4):257-261.
53. Woodward C.L., Hall A.M., Williams I.G., et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009, 10(8):482-487.
54. Van Rompay K.K., Durand-Gasselin L., Brignolo L.L., et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008, 52(9):3144-3160.
55. Núñez M., Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005, 28(1):53-66.